Connor, Clark & Lunn Investment Management (CC&L)’s Syndax Pharmaceuticals SNDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-10,532
| Closed | -$268K | – | 1439 |
|
|
2022
Q4 | $268K | Sell |
10,532
-25,280
| -71% | -$643K | ﹤0.01% | 995 |
|
|
2022
Q3 | $861K | Buy |
+35,812
| New | +$861K | 0.01% | 689 |
|
|
2021
Q4 | – | Sell |
-11,530
| Closed | -$220K | – | 1188 |
|
|
2021
Q3 | $220K | Buy |
+11,530
| New | +$220K | ﹤0.01% | 932 |
|